Sirotrend 1mg Tablet

• Prevention of kidney transplant rejection

Every medicine has some side effects that typically manage on their own as your body gets used to the medicine, but some people may experience severe side effects rarely. In that case, the patient should contact the doctor immediately.

Some common side effects of Sirotrend 1mg Tablet include:

• Edema (swelling)
• Stomatitis (Inflammation of the mouth)
• Non-melanoma skin cancer
• Hemolytic uremic syndrome
• Hypersensitivity
• Pericardial effusion
• Venous thrombosis
• Pulmonary embolism
• Pneumonitis
• Pleural effusion
• Nosebleeds
• Pancreatic inflammation
• Ascites (accumulation of fluid in the abdominal cavity)
• Osteonecrosis (reduced blood flow to the bones)
• Ovarian cysts
• Joint pain
• Increased blood lipid level
• Decreased white blood cell count (neutrophils)
• Herpes zoster
• Sepsis
• Kidney infection
• Cytomegalovirus infection

Contact your healthcare provider if you face any unusual or persistent side effects.

• Take Sirotrend 1mg Tablet in exact dose as prescribed by the doctor. The typical dose of this capsule varies with age and overall health factor of the patient. It can be taken with or without food but at a fixed time each day to get better results.
• It should be swallowed as a whole with water without crushing, chewing, or opening the capsule. Don't miss a dose or overdose the medicine.
  
  

• Sirotrend 1mg Tablet is used to suppress the body's immune system. It is an immunosuppressant that helps the body accept the new organ after transplant (heart, liver, and kidney).
• It comprises Sirolimus that is a macrolide compound that bind to FKBP-12. It also act as a mTOR inhibitor which inhibits mTOR pathways as a result, the immune response is suppressed.​
  

• Augustine, J. J., Bodziak, K. A., & Hricik, D. E. (2007). Use of sirolimus in solid organ transplantation. Drugs, 67(3), 369-391.https://pubmed.ncbi.nlm.nih.gov/17335296/
• Merkel, S., Mogilevskaja, N., Mengel, M., Haller, H., & Schwarz, A. (2006, April). Side effects of sirolimus. In Transplantation proceedings (Vol. 38, No. 3, pp. 714-715). Elsevier. https://pubmed.ncbi.nlm.nih.gov/16647452/
• Kelly, P. A., Gruber, S. A., Behbod, F., & Kahan, B. D. (1997). Sirolimus, a new, potent immunosuppressive agent. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 17(6), 1148-1156. https://pubmed.ncbi.nlm.nih.gov/9399599/
• Kahan, B. D. (2001). Sirolimus: a comprehensive review. Expert opinion on pharmacotherapy, 2(11), 1903-1917. https://pubmed.ncbi.nlm.nih.gov/11825325/
• McCormack, F. X., Inoue, Y., Moss, J., Singer, L. G., Strange, C., Nakata, K., ... & Trapnell, B. C. (2011). Efficacy and safety of sirolimus in lymphangioleiomyomatosis. New England Journal of Medicine, 364(17), 1595-1606. https://pubmed.ncbi.nlm.nih.gov/21410393/
• Sehgal, S. N. (2003, May). Sirolimus: its discovery, biological properties, and mechanism of action. In Transplantation proceedings (Vol. 35, No. 3, pp. S7-S14). Elsevier. https://pubmed.ncbi.nlm.nih.gov/12742462/